Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

INTRODUCTION: Patients with cancer have been prioritized for vaccination against severe acute respiratory syndrome coronavirus 2. Nevertheless, there are limited data regarding the safety, efficacy, and risk of developing immune-related adverse events (irAEs) associated with mRNA vaccines in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibino, Makoto, Uryu, Kiyoaki, Takeda, Takayuki, Kunimatsu, Yusuke, Shiotsu, Shinsuke, Uchino, Junji, Hirai, Soichi, Yamada, Tadaaki, Okada, Asuka, Hasegawa, Yoshikazu, Hiranuma, Osamu, Chihara, Yusuke, Kamada, Riko, Tobe, Shunichi, Maeda, Kazunari, Horiuchi, Shigeto, Kondo, Tetsuri, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220466/
https://www.ncbi.nlm.nih.gov/pubmed/35752437
http://dx.doi.org/10.1016/j.jtho.2022.05.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220466/
https://www.ncbi.nlm.nih.gov/pubmed/35752437
http://dx.doi.org/10.1016/j.jtho.2022.05.015

Ejemplares similares